- Home
- PMD vs CANF Comparison
PMD vs CANF Comparison
Compare PMD & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMD
- CANF
- Stock Information
- Founded
- PMD 1986
- CANF 1994
- Country
- PMD United States
- CANF Israel
- Employees
- PMD N/A
- CANF N/A
- Industry
- PMD Medical Specialities
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- PMD Health Care
- CANF Health Care
- Exchange
- PMD Nasdaq
- CANF Nasdaq
- Market Cap
- PMD 13.3M
- CANF 14.4M
- IPO Year
- PMD N/A
- CANF N/A
- Fundamental
- Price
- PMD $2.31
- CANF $2.67
- Analyst Decision
- PMD
- CANF Strong Buy
- Analyst Count
- PMD 0
- CANF 2
- Target Price
- PMD N/A
- CANF $14.00
- AVG Volume (30 Days)
- PMD 20.6K
- CANF 144.0K
- Earning Date
- PMD 11-07-2024
- CANF 11-15-2024
- Dividend Yield
- PMD N/A
- CANF N/A
- EPS Growth
- PMD N/A
- CANF N/A
- EPS
- PMD N/A
- CANF N/A
- Revenue
- PMD $20,787,000.00
- CANF $667,000.00
- Revenue This Year
- PMD N/A
- CANF $356.93
- Revenue Next Year
- PMD N/A
- CANF N/A
- P/E Ratio
- PMD N/A
- CANF N/A
- Revenue Growth
- PMD N/A
- CANF N/A
- 52 Week Low
- PMD $1.63
- CANF $1.81
- 52 Week High
- PMD $3.93
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- PMD 51.25
- CANF 66.63
- Support Level
- PMD $2.28
- CANF $1.87
- Resistance Level
- PMD $2.35
- CANF $2.84
- Average True Range (ATR)
- PMD 0.02
- CANF 0.20
- MACD
- PMD -0.00
- CANF 0.09
- Stochastic Oscillator
- PMD 50.00
- CANF 81.72
About PMD Psychemedics Corporation
Psychemedics Corp is engaged in providing testing services for the detection of drugs of abuse through the analysis of hair samples. The company operates through a single segment of drug testing services which include training for the collection of samples and storage of positive samples for its customers for an agreed-upon fee per unit testing of samples. The testing methods of the company utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. They provide testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples. Geographically it generates the majority of its revenue from the United States.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).